Please login to the form below

Not currently logged in
Email:
Password:

SHP465

This page shows the latest SHP465 news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

Formerly known as SHP465, Mydayis has been approved to treat ADHD in children aged over 13 and adults, as in younger patients it has higher rates of adverse reaction such as

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    While Intuniv remains an important ADHD product for Shire, the company's main near-term ambition in the category is securing approval for SHP465, a mixed amphetamine salt product that it

  • Shire pitching at adult ADHD product launch in 2017 Shire pitching at adult ADHD product launch in 2017

    Shire wants to develop a drug called SHP465 (triple-bead mixed amphetamine salts) for adult ADHD, but to satisfy the FDA will have to first carry out a trial of the ... SHP465 will provide 16 hours cover from a single tablet, extending from the morning

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics